Al-Thanoon et al. reported that several markers of metabolic syndrome (MetS) were improved by the administration of losartan (50 mg/day) or enalapril (20 mg/day).
1
Non-alcoholic liver disease (NAFLD) is considered a manifestation of MetS which is also associated with raised SUA levels. 9 Even abnormal liver function tests (LFTs) have been linked with increased vascular risk. 10 A post hoc analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study included 437 patients with coronary heart disease and moderately elevated (<3 × the upper limit of normal) LFTs [alanine (ALT) and aspartate aminotransferase (AST) activities]. 11 These patients experienced a greater CV benefit from atorvastatin compared with those with normal AST/ALT activities.
11 Therefore, it would be interesting to know whether weight reduction together with antihypertensive treatment was associated with changes in AST/ALT activities in the Al-Thanoon et al. study. 1 The weight loss (4.2 and 3.0 kg in the losartan and enalapril group, respectively) was quite marked over this 2 month study. 1 Did the patients receive lifestyle advice? Also, it is important to consider that any effects on SUA, HDL-C and LFTs might be weight-related. 
